Skip to search formSkip to main contentSkip to account menu

DORAVIRINE

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract Absorption, distribution, metabolism and elimination of doravirine (MK-1439), a novel non-nucleoside reverse… 
2019
2019
Doravirine is a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1… 
Highly Cited
2018
Highly Cited
2018
In Human Immunodeficiency Virus–1 treatment-naive adults, a fixed combination of doravirine/lamivudine/tenofovir disoproxil… 
Review
2018
Review
2018
Doravirine is a new HIV-1 non-nucleoside reverse transcriptase inhibitor that has demonstrated a good efficacy and safety profile… 
2017
2017
Background and ObjectiveDoravirine is a novel non-nucleoside reverse transcriptase inhibitor being developed for the treatment of… 
2017
2017
Background and ObjectiveDoravirine is a novel, next-generation, non-nucleoside reverse transcriptase inhibitor in development for… 
Highly Cited
2016
Highly Cited
2016
ABSTRACT Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1… 
2016
2016
ABSTRACT Doravirine is a novel, highly potent, nonnucleoside reverse transcriptase inhibitor that is administered once daily and… 
2015
2015
The development of an efficient and robust process for the production of HIV NNRTI doravirine is described. The synthesis… 
Highly Cited
2015
Highly Cited
2015
Background Doravirine is a novel non-nucleoside inhibitor of HIV-1 reverse transcriptase with potent activity against wild-type…